Perihilar Cholangiocarcinoma
17
6
7
3
Key Insights
Highlights
Success Rate
60% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
11.8%
2 terminated out of 17 trials
60.0%
-26.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (17)
LIver TrAnspLantation for Non-resectable Peri-HIlar cholangioCArcinoma (LITALHICA)
PD-1 Antibody Plus GEMOX as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma
Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA
Biliary Drainage Plus HAIC in Locally Advanced pCCA
Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma (POELH-III)
Liver Transplantation for Non-resectable Perihilar Cholangiocarcinoma
Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer
Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma
Neoadjuvant Gemcitabine and Cisplatin in Combination With Perioperative Pembrolizumab Versus Upfront Surgery for Patients With Primary Resectable and Borderline Resectable Perihilar and Distal Cholangiocarcinoma
Robotically Assisted Surgery For Perihilar Cholangiocarcinoma: A Prospective Study
Extent of Intrahepatic Infiltration of Perihilar Cholangiocarcinoma
Endoscopy and Radiology-guided Ablation for Inoperable Cholangiocarcinoma
Endoscopic Drainage of Presumed Resectable pCCA Using an Intrahepatic Plastic Stent With Retrieval String
Endobiliary Radiofrequency Ablation for Malignant Biliary Obstruction Due to Perihilar Cholangiocarcinoma
Minimally Invasive Versus Open Surgery for PHC
Endoscopic Versus Radiologic Biliary Drainage for Perihilar Malignant Obstruction
Prognosis of Nutritional Status for Surgical Peri Hilar Cholangiocarcinoma